(PharmaNewsWire.Com, May 08, 2017 ) According to Publisher, the Global Orphan Drug market is estimated at $145.89 million in 2016 and is expected to reach $265.63 million by 2022 growing at a CAGR of 10.5% from 2016 to 2022. Rising focus of big pharmaceutical companies on orphan drug improvement, increasing occurrence of rare diseases, government incentives for orphan medicine are some factors favouring the market growth. However, some factors such as high initial investment that leads to higher per patient treatment cost, reimbursement uncertainties and high cost of drug development are hindering the market. North America registered significant growth for the market during the forecast period due to rising healthcare spending, constructive government initiatives, growing occurrence of chronic diseases and small timeline required for orphan drug development.
Indications Covered: -Acute Myeloid Leukemia -Duchenne Muscular Dystrophy -Glioma -Graft vs Host Disease -Multiple Myeloma -Non-Hodgkin Lymphoma -Ovarian Cancer -Pancreatic Cancer -Renal Cell Carcinoma -Other Indications
Regions Covered: -North America -US -Canada -Mexico -Europe -Germany -France -Italy -UK -Spain -Rest of Europe -Asia Pacific -Japan -China -India -Australia -New Zealand -Rest of Asia Pacific -Rest of the World -Middle East -Brazil -Argentina -South Africa -Egypt
Company Profiling 12.1 Abbott Laboratories 12.2 AbbVie Inc. 12.3 Alexion Pharmaceuticals 12.4 Amgen, Inc. 12.5 Bayer Healthcare 12.6 Boehringer Ingelheim GmbH 12.7 Bristol Myers Squibb 12.8 Celgene Corporation 12.9 F. Hoffmann-La Roche AG 12.10 Genentech 12.11 Janssen Biotech, Inc. 12.12 Johnson & Johnson 12.13 Merck & Co., Inc. 12.14 Novartis 12.15 Pfizer Inc. 12.16 Roche Holding AG 12.17 Sanofi Aventis 12.18 Vertex Pharmaceuticals
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: